Companies ›Industrials ›AMARCM.BK

AMARCM.BK — SET (Bangkok) Business Support Services

Asia Medical & Agricultural Laboratory & Research Center PCL

—

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

6,51 %

Op margin

32,2 %

ROE

26,3 %

Net margin

32,3 %

Debt / equity

0,03

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Asia Medical & Agricultural Laboratory & Research Center PCL provides industrial services, primarily through its operations in the business support services sector.

Business. Asia Medical & Agricultural Laboratory & Research Center PCL (AMARCM.BK) is a provider of business support services operating within the Industrial & Commercial Services sector. The company is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorIndustrials

Business sectorIndustrial & Commercial Services

IndustryBusiness Support Services

ActivityIndustrial Services

Generated · model-assisted

Sell-side consensus

HOLD1 analysts

0 buy1 hold0 sell

Avg 12m price target4,30

Analyst recommendations

1 analysts · consensus Hold

Buy0

Hold1

Sell0

12-month price target

4,30

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

1 analysts · indicative

Ownership

—

not yet wired

Profitability→

26,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning AMARCM.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials · THIS SECTOR−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to AMARCM.BK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Asia Medical & Agricultural Laboratory & Research Center PCL (AMARCM.BK) is a provider of business support services operating within the Industrial & Commercial Services sector. The company is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorIndustrials

Business sectorIndustrial & Commercial Services

IndustryBusiness Support Services

ActivityIndustrial Services

AI synthesis

GENERATED

Asia Medical & Agricultural Laboratory & Research Center PCL maintains a strong liquidity position, with a current ratio of 4.78 and a cash and equivalents balance of 45.56 million THB. The company's debt-to-equity ratio is 0.03, indicating a conservative capital structure with minimal leverage. Free cash flow of 149.95 million THB supports operational flexibility and potential reinvestment.

Profitability metrics show a return on equity of 26.34% and a return on assets of 22.48%, both significantly above the typical thresholds for the Business Support Services industry. The operating margin, calculated as operating income of 158.27 million THB divided by revenue of 491.01 million THB, is 32.23%, which is robust compared to industry medians.

The company's revenue is concentrated in a single disclosed segment, with no geographic breakdown provided in the latest financial data. This lack of diversification may expose the company to regional economic fluctuations, though the specific impact is not quantified in the available data.

Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant revenue deltas reported in the outlook. Historical revenue of 491.01 million THB provides a baseline for future performance, though the absence of forward-looking guidance limits the ability to assess long-term growth potential.

Risk factors are minimal, with low liquidity and dilution risk scores. No immediate filing-based liquidity or dilution flags were detected, and the company has not issued any recent dilutive instruments. The absence of dilution pressure is supported by the identical basic and diluted share counts of 420 million shares.

Recent events include a single analyst recommendation of "Hold" with a mean price target of 4.30 THB. No strong buy or buy ratings were issued, and the company has not disclosed any material events in its recent filings or transcripts that would suggest a significant shift in business strategy or performance.

Key takeaways

Asia Medical & Agricultural Laboratory & Research Center PCL has a strong liquidity position with a current ratio of 4.78 and a low debt-to-equity ratio of 0.03.
The company demonstrates high profitability, with a return on equity of 26.34% and a return on assets of 22.48%.
Revenue is concentrated in a single segment, with no geographic diversification disclosed, potentially increasing exposure to regional economic risks.
Analysts have issued a "Hold" recommendation with a mean price target of 4.30 THB, indicating a neutral outlook.
The company faces minimal liquidity and dilution risks, with no immediate filing-based flags detected.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

—

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$601.9M

Net cashⓘ

$24.5M

Current ratioⓘ

4.8

Debt / equityⓘ

0.0

ROAⓘ

22.5%

ROEⓘ

26.3%

Cash conversionⓘ

131.0%

CapEx / revenueⓘ

-10.2%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,39

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-14 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,39
Revenue	—no estimate	—no estimate	525,0M THB
Operating income	—no estimate	—no estimate	—no estimate

Full-year consensus mean (period as reported by source) · consensus in THB. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy0

Hold1

Sell0

Strong sell0

12-month price target$4,30 · Median $4,30

Low $4,30High $4,30

EPS surprise

−3,1 %

reported vs consensus · miss

Revenue surprise

−6,5 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,30

Mean$4,30

Median$4,30

High$4,30

Spot—

12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin32,2 %Best in class

Net Margin32,3 %Best in class

ROE26,3 %Best in class

Capex / Rev-10,2 %Bottom quartile

D/E0,03Above median

Cash Conv1,31Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Asia Medical & Agricultural Laboratory & Research Center PCL Market data — financials · 2026-05-27
Asia Medical & Agricultural Laboratory & Research Center PCL Market data — analyst estimates · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

AMARCM.BKCanonical

SET (Bangkok) · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread